DaVita expects $20 million in incremental operating income growth in 2026. Despite financial headwinds, they remain confident in sustaining profit growth through clinical excellence. Initiatives like flu vaccination and GLP-1 adoption aim to improve patient outcomes and support volume growth. A strategic partnership with Elara Caring aims to enhance patient care.

DaVita’s patient-centered strategy supports business objectives by improving quality of life and reducing hospitalizations. Clinical initiatives target 2% volume growth, focusing on cost efficiency and innovation. Adjusted operating income growth over the next 3 years is projected at 3% to 7%, with an opportunity to exceed long-term adjusted EPS guidance of 8% to 14%.

In 2025, DaVita saw $2.094 billion in adjusted operating income and $10.78 in adjusted EPS. U.S. dialysis treatments declined slightly, but revenue per treatment growth accelerated in the fourth quarter. Their 2026 guidance includes adjusted operating income between $2.085 billion to $2.235 billion and adjusted earnings per share of $13.60 to $15. In 2025, RPT saw a 4.7% increase, with patient care costs rising by $6 per treatment. International adjusted OI was $21 million, resulting in a full year adjusted operating income of $114 million. Capital allocation included repurchasing nearly 13 million shares for $1.8 billion.

For 2026, adjusted operating income is guided to have a midpoint of $2.16 billion, with assumptions for flat treatment volume and no improvement in non-flu mortality. U.S. dialysis costs are expected to grow 1.25% to 2.25%, driven by wage rate increases and G&A investments. Adjusted EPS for 2026 is expected to be $14.30. In 2026, the company expects a 33% increase in guidance, driven by higher operating income, lower share count, and the removal of losses at Mozarc. Free cash flow is estimated at $1.125 billion. Analysts are curious about the return to 2% volume growth and multi-year guidance, with a focus on capital deployment and share repurchases.

Analysts seek clarity on missed treatments and mortality trends in Q4, noting a correlation with a lag between the two metrics. The impact of the ACA headwind is expected to be $40 million this year, $70 million next year, and $10 million the year after. Open enrollment performed better than expected, with patients displaying sophistication in understanding insurance needs. The conversation has shifted to the importance of maintaining health insurance, with a focus on two distinct patient populations. Current patients are expected to be more resilient, while incoming CKD patients may not value insurance as much. The number of insured individuals is projected to grow over time.

Questions arise about the number of ACA patients receiving premium assistance, with detailed categories and income levels complicating the breakdown. The impact of the cyber headwind from 2025 and potential offsets in 2026 are discussed, along with initiatives on the reimbursement side.

An in-depth discussion on IKC performance in 2024 highlights shared savings, contracting, and system value. Confidence in continued growth is based on factors such as medication management, transitions of care, and interventions that collectively contribute to a positive impact.

Concerns are raised about the progression of kidney disease and the impact of new drugs on dialysis timelines. While no immediate shift has been observed, the effects of these drugs may take time to manifest. The management of CKD populations is a relatively new endeavor, with impacts yet to be fully realized. Javier Rodriguez discusses the Elara Caring investment, emphasizing the goal of good capital returns and improving patient outcomes, particularly for those using home health services. The focus is on reducing hospitalizations, readmissions, and missed treatments to enhance patient care both in and out of the clinic.

Joel Ackerman from the company addresses questions about the international business, highlighting a growth strategy that combines M&A and organic growth. The company expects margins to continue improving as they leverage fixed overhead costs. Ackerman notes that international operations have been consistent performers, contributing to overall operational income growth.

In response to inquiries about IKC losses, Joel Ackerman explains a natural slowdown in margin improvement due to the business maturing and increasing in size. The company anticipates a $20 million annual contribution to operational income growth, a decrease from previous years. Ackerman emphasizes the need to stabilize margins and manage expectations for future growth.

Regarding new patient starts in 2026, Joel Ackerman predicts a similar trend to previous years, with a higher commercial mix among new patients. He expects new starts to remain relatively flat unless there are significant improvements in mortality rates or missed treatment rates. Ackerman does not foresee a significant shift in patient mix for new starts.

Javier Rodriguez discusses efforts to increase flu vaccination rates, aiming to reach the 90th percentile as seen in the past. Currently at 80%, the company considers this rate healthy but seeks improvement. Rodriguez explains that flu vaccines typically increase in Q4 compared to Q3, impacting revenue per treatment and costs.

In a discussion about the dialysis population and potential growth outlook for 2027, Rodriguez acknowledges the differences from the MA population. Questions arise about the impact of advanced notices on growth projections for the upcoming year. Rodriguez appreciates the inquiry and considers factors that may influence growth projections for 2027. CMS has acknowledged underfunding for the ESRD population in MA, leading to a 6% increase in 2027. Coding regime changes apply, with a focus on clinical opportunities. A strong alignment between clinical ambitions and financial goals aims to improve patient care while delivering returns for shareholders.

The Motley Fool highlights “Double Down” stock recommendations for Nvidia, Apple, and Netflix. Investing $1,000 in these stocks when recommended yielded significant returns. Alerts for three new companies are available through Stock Advisor, emphasizing unique investment opportunities not to be missed.

This article is a transcript of a conference call by The Motley Fool. Errors may be present, and readers are encouraged to do their own research. The Motley Fool does not take responsibility for the content. The Motley Fool emphasizes its disclosure policy and advises readers to review the Terms and Conditions for additional details on liability.

Read more at Yahoo Finance: DaVita (DVA) Q4 2025 Earnings Call Transcript